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Jeffrey C. Murray2,*First, I thank Mary-Claire for the wonderful introduction.
As Mary-Claire noted, I moved here in 1967, when the
Red Sox clinched the pennant for the first time after a
long drought and then went on to play the St. Louis Cardi-
nals, as they do again this year. I became a Red Sox fan in
1967 and survived the disappointments of 1975 and 1986,
but eventually in 2004 they did win, and so I’m excited to
now have the opportunity to be in Boston once again for a
World Series.
I also wanted to acknowledge that we are celebrating the
50th anniversary of Massachusetts’s becoming the first
state to mandate phenylketonuria screening for newborns.
This is one of the first and possibly themost impactful pub-
lic-health successes that genetics has brought to us, and
this milestone will resonate in talks we hear over the
next few days as we increasingly see the application of
genetic knowledge to directly benefit individuals.
Today, I am going to focus in part on something that
most of you might not feel is an exciting topic—a strategic
plan for The American Society of Human Genetics (ASHG).1This article is based on the address given by the author at themeeting of The A
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The AmeBut, first I will summarize a bit of the history of the
Society—a few of the events that have helped form my
career—and then will spend a bit of time talking about
an ASHG strategic plan to stimulate you over the course
of the rest of this meeting to think about the Society. We
are at a critical time in genetics, and we hope that meetings
like this can help to stimulate us to think about where we
might be a few years from now. I also wanted to recognize
our staff, particularly Pauline Minhinnett and Joe McIner-
ney, our new executive vice president (EVP), who have
brought this meeting together, who had to deal with
changes in our EVP position, and who were acutely chal-
lenged in having to deal with the governmental budget
crisis that took place over the last couple of months.
Finally, I also thank all of you general members, committee
members, and board members who make the Society what
it is. My somewhat tongue-in-cheek comment is in part an
acknowledgment of the fact that although these speeches
recur year after year, it is the members who provide for
societal stability. Most of you are unlikely to remember
anything about this talk, but I do hope that you will
remember your mission as a member of the Society and
that you work to improve ASHG, your own work, and
the lives of others.
In a terrific article reviewing these meetings, Terry Has-
sold and Bronya Keats1 showed a curve of attendance
over the last 60 years. Their graph demonstrates an enor-
mous burst of growth that began in the 1970s, when we
had only a few hundred attendees at the annual meeting,
up to the 6,000 or 7,000 individuals who attend these
meetings today. So the good news is that we grew very
rapidly and became a large society that offers many,
many benefits to our membership. A possible concern is
also illustrated in their figure, where you can see a leveling
off in meeting attendance over the last decade, suggesting
that we might have saturated the human genetics mar-
ket—an issue we need to consider as we go forward.
I have also seen my personal history reflected in the his-
tory of human genetics and ASHG. I was born in 1949, the
Society in 1948, and as we all know, the 1950s heralded
both the structure of DNA and the normal chromosome
count of 46. I had a brother born in 1951 with trisomy
21, although his formal diagnosis wasn’t made until hismerican Society of HumanGenetics (ASHG) onOctober 22, 2013, in Boston,
.
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Figure 1. Pedigree of a Family Affected by the MspI Polymor-
phism
The 18 and 13 kb fragments are codominant alleles. The 6.8 kb
fragment shown is a nonpolymorphic band detected with MspI.
A 5 kb band found only in association with the 13 kb band is
not shown here, and two faint bands are seen between the 13
and 6.8 kb fragments.autopsy following his death at age 29. We suffered under
the standards of care of the medical community at the
time in that he was placed into an institution where he
stayed until his death. He never had surgery for his correct-
able congenital heart disease and died as a complication of
that condition. He also bore a startling physical resem-
blance to me, his older brother, demonstrating early on
for me that children and adults with Down syndrome
have many of their physical and behavioral traits
embedded in their DNA, just as any other family member
might. His treatment was very much in contrast to that
of my niece once removed, who was also born with tri-
somy 21 just a few years ago and who had very successful
surgery performed shortly after birth. She is fully inte-
grated into her family with her wonderful, loving parents
and younger brother, and I think she demonstrates the
growth in not only our knowledge and our technology
but also our ability to deliver medicine that can provide a
family context to the benefit of all.
It was in the 1960s, and just before I came to college here
in Boston, that while taking high school biology from my
teacher, Mr. Pine, I was most likely imprinted with a career
in genetics by his tangible enthusiasm for questions of
genetics in general and specifically around finally knowing
the exact chromosome number of 46. He was the first
among many of my teachers who conveyed a love and
enchantment with our discipline. Many of us will have
similarly benefitted from charismatic teachers, and it is
highly appropriate that a major mission of our Society
lies in fostering college and precollege genetics awareness.
While attending school in Boston, I was very fortunate
to get a job in a lab where DNA technology was at the fore-
front. I worked in Gobind Khorana’s lab for several years as
a lab technician on DNA synthesis for his postdoctoral
fellows Marv Caruthers and Hans van de Sande; there I320 The American Journal of Human Genetics 94, 319–323, March 6received my first training on how to plan and execute an
experiment. A few years later, in 1975, probably the single
most important stimulus to my future career came when I
went to medical school at Tufts and had the opportunity to
work under Murray Feingold for a summer on a research
study on the effect of maternal diabetes on the fetus. Prob-
ably more important than the research (which was never
published but did show an increase in neural-tube defects
[NTDs]) was the chance to observe Murray and his fellow
Lou Bartosheshky in their dedicated care for patients.
Over the 7 years that I was a medical student and a resident
at Tufts, I repeatedly saw their incredible commitment to
the patients and their families. Although I will never
achieve this same capacity for passion and commitment,
I’ll always be grateful for the message that he sent about
the primary importance of patient and family care. I was
equally lucky to take my first faculty position in Iowa,
where the same messages were passed on to me by my
mentor there, Jim Hanson.
After I left Tufts, Iwent to a postdoctoral fellowship under
Arno Motulsky, and it was under Arno’s direction that my
love formolecular biology and its application in human ge-
netics flowered. In parallel, Arno fosteredmy interest in the
social and ethical aspects of genetics. Shown here is a figure
taken from an article that was the first scientific article on
which I played a major role (Figure 1). It shows a single
SNP, or as it was known back in the day, a restriction-frag-
ment-length polymorphism, segregating in Arno’s family.
We were able to get a very nice publication in Proceedings
of the National Academy of Sciences2 because we identified a
few SNPs. It is likely that there are over a billion SNPs char-
acterized every day now. The technology advances where
you can go from identifying a single SNP and it’s having
some resonance in the scientific community to the scale
on which genomics operates today is truly amazing. I’m
alsovery grateful toArnoandhis family,whoprovided their
DNA samples for our analysis (Figure 1).
Presidential lectures call us to look back at what people
before us have said, so I’m going to use some quotations
from a few earlier presidents to illustrate some points about
the Society and to segue into our strategic planning goals.
Jim Neel was the first president who I knew personally,
and he noted, ‘‘It would be redundant in this company
to extol the advantages of membership in [ASHG].Our
Society, by what I am sure is careful design, has adopted
an entirely different pattern.Apparently the only require-
ment for our Presidential Address is that the speaker talk
about some subject close to his heart at the moment.’’3
Clarke Fraser, who I think was probably the coolest presi-
dent, said this: ‘‘It was suggested that I should call my
talk ‘Ponderings of a Peripatetic Pediatrician,’ but the fact
that I’m not a pediatrician spoils the alliteration. So I will
air some thoughts that are either too trivial, or vague, or
so completely unsupported by data, that I could not pre-
sent them anywhere but in a Presidential address.’’4 So,
I’m going to take advantage of Professor Fraser’s encomium
and do some speculating., 2014
Clarke Fraser was the first president (in 1961) who
mentioned DNA in his address. I was surprised that it
took eight years after the DNA structure was identified
for DNA to get a mention in a presidential address. Fraser
was prescient also in that he said, ‘‘Let’s admit that the
DNA-RNA code isn’t the whole answer. There are, no
doubt, other systems that transmit genetic information.-
that may be very important in developmental processes. It
may well be that not all familial, intrinsically determined
diseases and defects will be traced to alterations in the
DNA.’’4 Now, some 50 years later, this insight mirrors
many of the ways in whichwe now think about the genetic
causes of disease residing not only in the DNA sequence.
Victor McKusick, who is probably our president most
embedded in all aspects of genetics, talked at length about
the clinical connections that we have in our Society. In
1974 he noted, ‘‘Do we wish to become involved with cre-
dentialing, recertification, formal continuing education,
self-assessment, quality assurance, medical audit?.Ques-
tions about credentialing of non-MD’s who play important
roles in the delivery of genetic services will arise. Jurisdic-
tional disputes between medical genetics and laboratory
medicine.over cytogenetic and biochemical determina-
tion conceivably will also arise. Questions of reimburse-
ment for genetic services by third-party payers have
already arisen.’’5 As Victor predicted, we soon went on to
confront many of these issues (and we deal with them still)
during our separation from the American College of Med-
ical Genetics and our split from the genetic counselors. As
Victor noted, ‘‘When some form of national health insur-
ance is implemented, these questions will become even
more pressing.’’5 Well, it’s hard to think of anything that’s
been more pressing for all of us over the last few months
than the disputes that have arisen over the Affordable
Care Act and the devastating impact that it has had on
everybody in this audience in terms of not only their
research but also their ability to provide care and pursue
their careers.
I was fortunate to be working in Arno’s lab when he went
to Israel in the early 1980s to participate in a trial in absen-
tia of Josef Mengele, who had been a physician in Ausch-
witz and who tortured and experimented on twins and
many others. In his address, Arno said, ‘‘Let us not forget
that human genetics was horriblymisused by the Nazi gov-
ernment of Germany in the 1930s. Somewhat later, from
the opposite end of the political spectrum, the Lysenkoists
destroyed human genetics in the Soviet Union. As respon-
sible human geneticists, we must speak out and differen-
tiate those findings which are generally accepted biological
realities from others which are interpretations and flights
of fancy.’’6 One of the most valuable lessons that came
out of my contact with Arno was the recognition of how
important politics is in science. We continue to be chal-
lenged by the social and ethical aspects of science and
medicine driven by both technology and culture.
The last comment I have on past presidents reflects on
our logo outlining ASHG’s mission, ‘‘To discover, toThe Ameeducate, and to advocate.’’ Each of the last several presi-
dents reached out to us as individuals to go beyond the
research that we do and to do more than what we find our-
selves delivering in our ‘‘day jobs.’’ Ed McCabe had a
wonderful riff on evolution and the extensive discussion
of complex traits, and the selection of single-nucleotide
variants via evolutionary selection reinforces that physi-
cians should incorporate evolution and its impact as a
context in which to understand disease.7 Rod McInnes
gave a verymoving talk on the relationship that geneticists
have with culture and talked about native Canadians and
how we need to be sensitive to cultures outside our
own.8 Lynn Jorde encouraged us to extend ourselves
beyond the laboratory to work to educate everyone from
K–12 to judges and lawyers.9 Finally, in her wonderful pre-
sentation last year on the scientist as a citizen of the world,
Mary-Claire King helped us to see the work we do in its full
global context.10
Let me provide a few specifics about our ASHG strategic
plan. Professional societies such as ours can benefit from
periodically focusing on the landscape of their field and re-
considering past mission statements in determining how
to best serve their membership. An outline of a strategic
vision was put together by Joe McInerney and our staff
over the last several months. Three target areas rose to
prominence. The first is to assess the status and likely
future of research, translational medicine, education, and
advocacy. The second is to ensure that we serve our mem-
bership and continue to be the leading professional society
in human genetics all while working in concert with other
genetic societies. Finally, the third is to consider goals and
strategies for the structure and function of our Society in all
of its aspects over the next 3–5 years and to begin to think
beyond 5 years as well. We will have an open forum to
begin this process on Thursday night and will then use
websites and social media to provide additional mecha-
nisms for input. We are particularly eager for younger
members of the Society to help us think about how we
can make this meeting better for all of us going forward.
Next, we have had an enormously successful journal
built on a series of terrific editors who have raised the qual-
ity and impact factor of the premier journal dedicated to
human genetics. All of us strive to get our best work pub-
lished in the American Journal of Human Genetics, but the
nature of journals is changing. David Nelson, our current
editor, is faced with the enormous challenge of open-
access journals, the generation of new journals in the
same space of genetics, and theneed todistinguish between
print publications and electronic publications. Our Society
has always had some balance between basic translational
and clinical sciences, and going forward, we need to
continue to considerwhere the fulcrumpoints lie. A further
challenge is the balance of the subdisciplines—computa-
tional biology and bioinformatics—playing larger roles in
our meetings and journal. Over our 60-year history, we
have seen thewaxing andwaning ofmany different subdis-
ciplines—clinical, biochemical, population, behavioral,rican Journal of Human Genetics 94, 319–323, March 6, 2014 321
and counseling genetics, etc. Going forward, we need to be
able to anticipate changes to fields and emphasis and to be
leaders in working with them as they develop. Genetics
continues to be controversial in that not everybody
embraces genetics as something useful and important.
Arguments continue to rage over genetically modified
organisms, prenatal diagnosis, DNA sequencing, forensic
testing, patenting, and all of the many important social,
ethical, and legal challenges we confront daily.
In putting this meeting together, we were challenged by
the possibility that many of our members, particularly
those who are United States federal employees, might
not be able to attend the meeting. Because of the govern-
ment shutdown of 2013, we were forced to cancel sessions,
reschedule others, and then re-reschedule still more. This
sad episode of failed governance only further highlights
the impact of the sequester on funding, which has dropped
National Institutes of Health budgets by almost 6% over
the last year, a tragic loss for science and medicine. There
is no better career to be involved in than genetics and to
both see the beauty of discovery and use that new knowl-
edge to improve the health of others. But at the same time,
there are the realities of how politics drives and influences
funding. We must encourage our students as they become
accomplished scientists and develop a passion for research
to also become involved in understanding the role of pol-
itics in science and to work toward supporting those indi-
viduals who will foster those programs and research efforts
that they think are most important.
A final bit of proselytizing that I will use this bully pulpit
for was stimulated by an email I received from Godfrey
Oakley a fewweeks ago. Godfrey was at the Centers for Dis-
ease Control for many years and was the primary force
behind the introduction of folic acid food fortification in
the United States, which has had such an enormous impact
ondecreasing theburdenofNTDs.Godfreywrote tomeand
said, ‘‘If you haven’t finished your talk yet, youmight think
about this,’’ and he included a copy of an article that he and
Bob Brent had written a few years ago, the topic of which
was The Fierce Urgency of Now.11 So the final message
that I want to leave with you is on that urgency of now. I
began doing work in the Philippines in the mid-1980s and
for the first time saw children with neonatal tetanus. Over
the first several years that I went to the Philippines, I would
routinely see five or six infants die with neonatal tetanus in
public-health hospitals serving the indigent population in
the Philippines; these infants were affected because their
mothershadnot received tetanusvaccinations, their umbil-
ical cords had been cut nonsterilely, and they came to care
too late for treatment. I remember thinking that the first
time I saw a child with tetanus, I didn’t even know that
tetanus was a problem that existed in the world anymore,
but I soon learned that although it had been eradicated in
the United States, it was still epidemic elsewhere. I had
even personally benefitted from the work that the March
of Dimes and others did on developing a polio vaccine. I
had polio when I was 4 years old, but my own children322 The American Journal of Human Genetics 94, 319–323, March 6were free from it because they were vaccinated for polio
and immunized against tetanus. So when I learned that
800,000 infants were dying of neonatal tetanus each year
in themid-1980s, I was just completely astounded, particu-
larly because not a single one of those deaths was in the
United States. Over the past 30 years, through philan-
thropies and the World Health Organization and others,
the burden of neonatal tetanus has now dropped to below
50,000, but there are still almost 50,000 unnecessary deaths
a year from one totally preventable cause. Themessage that
Godfrey and Bob had and that I amnowhappy to convey is
that all of us need to think not only about our own science,
about the patient thatmight be in front of us right now, and
about the work that we do as a part of our own culture and
education but also about spending a small part of our lives
thinking about those problems that are immediately
addressable right now but where we lack the political will
or funding. There are babies dying today unnecessarily,
and I encourage everyone here to spend at least a few
percent of their lives and careers thinking about and ad-
dressing those acute problems.
Okay, the big finish. Two years ago, when I learned that I
was going to be president, I received an email from Rod
McInnes, who was at that time the serving president.
Rod wrote to me, ‘‘Jeff, once a week for the next 2 years
you will wake up at night in a cold sweat, anxious about
the Presidential Address. Trust me. Ciao.’’ Well, Rod was
right, and although I can’t say that every single week
over those 2 years I woke up in a cold sweat some night,
I can tell you that every night for the last week I have wo-
ken up in a cold sweat, so I’m very glad that this is almost
over and equally glad that I had an opportunity to convey
to you both a personal message and a larger message for
this Society. I hope you will spend some of your time
thinking about ASHG and how we can improve and also
how we can address right now those issues of immediate
health impact in the world at large.
Lastly, some acknowledgments. Over the years, I have
had many students, staff, nurses, genetic counselors, and
colleagues who have really made my scientific career
enjoyable, wonderful, fun, and all the things that should
encourage you who are young to go into science. I will
choose four specific names to note because these are peo-
ple without whom I would not have had a scientific career,
nor four friends who have really made this career so enjoy-
able. Ken Buetow, Kaare Christensen, Brian Schutte, and
Mary Marazita have all been awesome scientific colleagues
who became friends and have made the life of a scientist
enjoyable almost every single minute. I want to thank
the staff and the membership of ASHG for the opportunity
to work with all of you. Next, patients and families who I
still have the opportunity to serve and who I learn from
every day about their strength and their ability to carry
on. And then lastly and most importantly, my wife, Ann
Marie McCarthy, our oldest son, Ryan, who was
born down the street at the Boston Hospital for Women
Lying-In Division some 33 years ago, and our two younger, 2014
kids, Chris and Katie, my daughters-in-law, Sharmala and
Alma, and our first grandchild, Fatima, all of whom will
live in and make a better world.References
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